EXCLUSIVE: Anixa Biosciences Tells Benzinga 'IND follows encouraging findings of necrosis, inflammation and T cell infiltration in tumor biopsy of patient in lowest dose cohort'
Portfolio Pulse from Benzinga Newsdesk
Anixa Biosciences reported encouraging findings of necrosis, inflammation, and T cell infiltration in a tumor biopsy of a patient in the lowest dose cohort, which could be a positive indicator for their ongoing clinical trials.
July 23, 2024 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anixa Biosciences reported promising biopsy results in their lowest dose cohort, showing necrosis, inflammation, and T cell infiltration. This could be a positive indicator for their ongoing clinical trials.
The positive biopsy results suggest that Anixa Biosciences' treatment is having the desired effect, which could lead to successful clinical trial outcomes. This news is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100